Phase 2 Prostate Clinical Trials
369 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 369 trials
Recruiting
Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Colorectal, CancerGastric CancerBiliary Tract Cancer+4 more
AstraZeneca454 enrolled96 locationsNCT05489211
Recruiting
Phase 2
A Study of Tarlatamab for People With Prostate Cancer
Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center32 enrolled10 locationsNCT07111507
Recruiting
Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled578 locationsNCT03866382
Recruiting
Phase 2
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
Prostate CancerProstate AdenocarcinomaProstatic Neoplasms
National Cancer Institute (NCI)42 enrolled1 locationNCT05616650
Recruiting
Phase 1Phase 2
First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
Metastatic Prostate Cancer
AstraZeneca42 enrolled8 locationsNCT07529717
Recruiting
Phase 1Phase 2
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals123 enrolled19 locationsNCT07226986
Recruiting
Phase 1Phase 2
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
Cancer of ProstateProstate Neoplasms
National Cancer Institute (NCI)86 enrolled1 locationNCT04633252
Recruiting
Phase 2
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Prostate CancerHigh-risk Prostate Cancer
Icahn School of Medicine at Mount Sinai40 enrolled1 locationNCT07027124
Recruiting
Phase 2
PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
Prostate CancerProstate AdenocarcinomaHormone Sensitive Prostate Cancer
University of Miami34 enrolled1 locationNCT06392295
Recruiting
Phase 2
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
Prostate Cancer
University of Chicago57 enrolled1 locationNCT05790213
Recruiting
Phase 2
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Prostate Cancer Clinical Trials Consortium126 enrolled5 locationsNCT06844383
Recruiting
Phase 1Phase 2
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Metastatic Prostate Cancer
AstraZeneca177 enrolled52 locationsNCT07181161
Recruiting
Phase 1Phase 2
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
Stage IVB Prostate Cancer AJCC v8Metastatic Malignant Neoplasm in the BoneMetastatic Castration-Resistant Prostate Carcinoma+1 more
National Cancer Institute (NCI)90 enrolled32 locationsNCT04071236
Recruiting
Phase 2
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Metastatic CancerCastrate Sensitive Prostate CancerNeoplasm, Prostate+1 more
Sun Pharmaceutical Industries Limited192 enrolled12 locationsNCT05422911
Recruiting
Phase 2
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
Prostate Cancer
M.D. Anderson Cancer Center30 enrolled1 locationNCT05873192
Recruiting
Phase 1Phase 2
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Prostate Cancer
Memorial Sloan Kettering Cancer Center50 enrolled12 locationsNCT06457919
Recruiting
Phase 1Phase 2
HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
Breast CancerProstate Cancer
University of Virginia23 enrolled1 locationNCT07441889
Recruiting
Phase 2
Using FAPI PET/MRI to Evaluate Prostate Cancer
Prostate CancersProstate Cancer Metastatic Disease
University of Wisconsin, Madison30 enrolled1 locationNCT06675357
Recruiting
Phase 1Phase 2
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Advanced Prostate CancerMetastatic Prostate Cancer
Genentech, Inc.260 enrolled2 locationsNCT07567846
Recruiting
Phase 2
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Metastatic Hormone Sensitive Prostate Cancer
Novartis Pharmaceuticals150 enrolled67 locationsNCT06991556